Invivyd Names Marc Elia CEO Ahead Of VYD2311 Phase 3 COVID Readout

Invivyd has appointed current chairman Marc Elia as chief executive officer, combining the two roles as the company approaches a key clinical readout for its lead COVID antibody program. The company said Elia has been a board member since 2022 and helped design its scientific and corporate strategy.

The timing ties the leadership change directly to execution risk. Invivyd is preparing for top-line data in the third quarter of this year from a phase 3 study of VYD2311, a monoclonal antibody being evaluated for the prevention of symptomatic COVID in adults and adolescents.

Why The Timing Matters

This is less a routine management shuffle than a transition staged around a single high-stakes asset. With VYD2311 carrying the near-term story, placing the chairman in the CEO seat suggests Invivyd wants tighter control over strategy and messaging heading into a data event that could shape both development plans and financing options.

Elia’s own comments also show how the company is trying to frame the product’s role. In a release, he said he had “struggled with the effects of long COVID” and added that Invivyd aims to protect patients from COVID beyond the limits of vaccines. That positions the company around continued unmet need rather than a broad reopening of pandemic-era prevention markets.

The Program In Focus

The source identifies VYD2311 as Invivyd’s lead monoclonal antibody program and says the phase 3 study is testing prevention of symptomatic COVID in adults and adolescents. No efficacy data were disclosed yet, so the immediate issue is not comparative performance but whether the program can produce a readout strong enough to validate the company’s antibody approach.

Elia said Invivyd and its antibody technologies have the potential to “revolutionize COVID prevention, and infectious disease medicine more broadly.” The harder business signal is narrower: the company is being judged first on whether one late-stage COVID study can support a durable role for monoclonal antibodies in prevention.

Broader Executive Moves This Week

The same roundup also detailed other leadership changes across biotech. Vertex Pharmaceuticals said that, alongside the completion of its acquisition of Crinetics, COO and CFO Charles Wagner will take on an expanded COO role overseeing integration of Crinetics, while senior vice president of finance Jonathan Poole will assume CFO responsibilities on January 1.

Inventiva named Chris Benecchi chief operating officer as it awaits phase 3 data for lanifibranor in metabolic dysfunction-associated steatohepatitis and prepares for potential commercialization. Elsewhere, The Emmes Group promoted Rama Kondru to CEO, Beam Therapeutics appointed Eric Foster chief commercial officer, and Acrivon Therapeutics named Michaela Levin chief business officer.

For Invivyd, however, the significance is more concentrated. Unlike broader C-suite buildouts, this change arrives immediately before a defined catalyst, making it a strategic handoff centered on one upcoming readout rather than a long-cycle organizational refresh.